Meilania Saraswati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Meilania Saraswati has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Cahyani Gita Ambarsari
School of Pharmacy, Biodiscovery Institute, University of Nottingham, University Park Campus, East Drive, Nottingham NG7 2RD, UK
4 shared publications - Agus Rizal Ardy Hariandy Hamid
Department of Urology Jakarta Cipto Mangunkusumo Hospital / Faculty of Medicine, Universitas Indonesia
3 shared publications Agus Rizal Ardy Hariandy Hamid
Department of Urology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
2 shared publicationsAria Kekalih
Department of Community Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
2 shared publicationsChaidir Arif Mochtar
Department of Urology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
2 shared publications- Chaidir Arif Mochtar
Department of Urology, Faculty of Medicine/Universitas Indonesia, Cipto Mangunkusumo General Hospital, Jakarta
2 shared publications
Latest Publications
- Open Access
- 6 January 2026
- Published by Faculty of Medicine, Universitas Indonesia in Medical Journal of Indonesia
- Vol. 35 (1)
SOX2 expression in the primary tumor of castration-naive metastatic prostate adenocarcinoma in association with metastasis extent
BACKGROUND Poor prognosis in patients with metastatic prostate adenocarcinoma (mPCa) may be due to the expression of stem cell-related genes. This study aimed to demonstrate the association between the expression of cancer stem cell markers and metastasis in patients with castration-naive mPCa. METHODS This cross-sectional, analytical study investigated a formalin-fixed paraffin-embedded prostate specimens from patients diagnosed in Cipto Mangunkusumo Hospital. Patients aged ≥50 years old were grouped based on the extent of metastases (high-volume disease [HVD] and low-volume disease [LVD]). In each case, immunohistochemical staining for CD133, CD44, SOX2, and androgen receptor was performed and analyzed using H-score. All data were recorded and analyzed using SPSS software version 20.0. RESULTS A total of 61 patients were recruited from 2020 to 2023 and divided into the HVD (n = 38) and LVD (n = 23) groups, with a mean age of 67.9 years. 45 of the patients had International Society of Urological Pathology (ISUP) grade 5 disease, while 16 of them had grade <5. A significant difference of ISUP grade and PSA serum level was observed in the HVD versus LVD group (p = 0.017 and <0.001, respectively). Additionally, a significant association was found between SOX2 expression and metastatic extent. CONCLUSIONS The LVD group showed higher SOX2 expression in the primary tumor compared to the HVD group. Different SOX2 expressions in various sites and stages may be due to the cancer cells’ systemic network.
- 6 January 2026
- Published by Faculty of Medicine, Universitas Indonesia in Medical Journal of Indonesia
- Vol. 35 (1)
Open AccessSOX2 expression in the primary tumor of castration-naive metastatic prostate adenocarcinoma in association with metastasis extent
BACKGROUND Poor prognosis in patients with metastatic prostate adenocarcinoma (mPCa) may be due to the expression of stem cell-related genes. This study aimed to demonstrate the association between the expression of cancer stem cell markers and metastasis in patients with castration-naive mPCa. METHODS This cross-sectional, analytical study investigated a formalin-fixed paraffin-embedded prostate specimens from patients diagnosed in Cipto Mangunkusumo Hospital. Patients aged ≥50 years old were grouped based on the extent of metastases (high-volume disease [HVD] and low-volume disease [LVD]). In each case, immunohistochemical staining for CD133, CD44, SOX2, and androgen receptor was performed and analyzed using H-score. All data were recorded and analyzed using SPSS software version 20.0. RESULTS A total of 61 patients were recruited from 2020 to 2023 and divided into the HVD (n = 38) and LVD (n = 23) groups, with a mean age of 67.9 years. 45 of the patients had International Society of Urological Pathology (ISUP) grade 5 disease, while 16 of them had grade <5. A significant difference of ISUP grade and PSA serum level was observed in the HVD versus LVD group (p = 0.017 and <0.001, respectively). Additionally, a significant association was found between SOX2 expression and metastatic extent. CONCLUSIONS The LVD group showed higher SOX2 expression in the primary tumor compared to the HVD group. Different SOX2 expressions in various sites and stages may be due to the cancer cells’ systemic network.
- Open Access
- 1 January 2025
- Published by S. Karger AG in Case Reports in Nephrology and Dialysis
- Vol. 15 (1) , 15-25
Dent Disease 1 Presented Early with Bartter-Like Syndrome Features and Rickets: A Case Report
Introduction: Dent disease (DD) is characterized by a triad of low-molecular-weight proteinuria, hypercalciuria, and nephrocalcinosis/nephrolithiasis. However, some cases were confounded by other clinical symptoms and signs, namely, hypokalemia and rickets, which resulted in misleading diagnoses. A diagnosis of DD could be delayed even in high-resource countries due to its variability of phenotypes and rarity, causing a lack of awareness in both medical practitioners and parents. Moreover, in low-resource countries, laboratory test limitations can hinder the diagnosis. Case Presentation: A thirteen-year-old boy presented with an acute episode of severe hypokalemia following vomiting due to COVID medication side effects. He had lower extremities weakness, salt craving, and polydipsia since childhood which were not thought to be unusual by the parents. He had a history of intrauterine polyhydramnios and maternal miscarriages. A physical examination showed hypotension, short stature, and genu valgum. His laboratory workup displayed hypokalemic metabolic alkalosis and increased urine potassium, chloride, transtubular potassium gradient, and calcium/creatinine ratio. He also had hypophosphatemia, hypomagnesemia, and decreased kidney function. Severe osteopenia was prominent on radiologic examination of all extremities. Subsequent laboratory samples sent overseas revealed low-molecular-weight proteinuria and a pathogenic variant in the CLCN5 gene confirming X-linked DD 1. Conclusion: This case report highlights the importance of considering DD in differential diagnoses of children with the pseudo-Bartter syndrome, that is, renal salt and potassium wasting, with or without hypercalciuria and nephrocalcinosis. Additionally, in children with rickets and proteinuria, urinary low-molecular-weight protein measurement could assist in screening for the possibility of DD, particularly in low-resource settings.
- 1 January 2025
- Published by S. Karger AG in Case Reports in Nephrology and Dialysis
- Vol. 15 (1) , 15-25
Open AccessDent Disease 1 Presented Early with Bartter-Like Syndrome Features and Rickets: A Case Report
Introduction: Dent disease (DD) is characterized by a triad of low-molecular-weight proteinuria, hypercalciuria, and nephrocalcinosis/nephrolithiasis. However, some cases were confounded by other clinical symptoms and signs, namely, hypokalemia and rickets, which resulted in misleading diagnoses. A diagnosis of DD could be delayed even in high-resource countries due to its variability of phenotypes and rarity, causing a lack of awareness in both medical practitioners and parents. Moreover, in low-resource countries, laboratory test limitations can hinder the diagnosis. Case Presentation: A thirteen-year-old boy presented with an acute episode of severe hypokalemia following vomiting due to COVID medication side effects. He had lower extremities weakness, salt craving, and polydipsia since childhood which were not thought to be unusual by the parents. He had a history of intrauterine polyhydramnios and maternal miscarriages. A physical examination showed hypotension, short stature, and genu valgum. His laboratory workup displayed hypokalemic metabolic alkalosis and increased urine potassium, chloride, transtubular potassium gradient, and calcium/creatinine ratio. He also had hypophosphatemia, hypomagnesemia, and decreased kidney function. Severe osteopenia was prominent on radiologic examination of all extremities. Subsequent laboratory samples sent overseas revealed low-molecular-weight proteinuria and a pathogenic variant in the CLCN5 gene confirming X-linked DD 1. Conclusion: This case report highlights the importance of considering DD in differential diagnoses of children with the pseudo-Bartter syndrome, that is, renal salt and potassium wasting, with or without hypercalciuria and nephrocalcinosis. Additionally, in children with rickets and proteinuria, urinary low-molecular-weight protein measurement could assist in screening for the possibility of DD, particularly in low-resource settings.
- Open Access
- 30 April 2024
- Published by Duzce Medical Journal in Düzce Tıp Fakültesi Dergisi
- Vol. 26 (1) , 88-90
Pulmonary Alveolar Proteinosis Secondary to Chronic Ethylene Oxide Occupational Inhalation
In this case report, a 40-year-old male patient with a persistent and productive cough lasting over 2 weeks, accompanied by dyspnea, who received an anti-tuberculosis drug regimen for 12 months without any clinical improvement at a different hospital before being referred to Persahabatan Central General Hospital was presented. In-depth clinical, and radiological investigations, the periodic acid-Schiff (PAS)-positive related to pulmonary alveolar proteinosis (PAP) confirmed through transbronchial biopsy (TBB). PAP is a rare lung disease with exceptionally low prevalence and incidence, Notably, the patient’s occupational environment played a crucial role in the diagnosis, as we identified occupational PAP secondary to chronic inhalation of ethylene oxide in a poorly ventilated work setting and inadequate respiratory protection. The patient was administered inhaled filgrastim (1 vial) at four intervals over 30 days, yielding favorable and satisfactory clinical as well as radiological outcomes.
- 30 April 2024
- Published by Duzce Medical Journal in Düzce Tıp Fakültesi Dergisi
- Vol. 26 (1) , 88-90
Open AccessPulmonary Alveolar Proteinosis Secondary to Chronic Ethylene Oxide Occupational Inhalation
In this case report, a 40-year-old male patient with a persistent and productive cough lasting over 2 weeks, accompanied by dyspnea, who received an anti-tuberculosis drug regimen for 12 months without any clinical improvement at a different hospital before being referred to Persahabatan Central General Hospital was presented. In-depth clinical, and radiological investigations, the periodic acid-Schiff (PAS)-positive related to pulmonary alveolar proteinosis (PAP) confirmed through transbronchial biopsy (TBB). PAP is a rare lung disease with exceptionally low prevalence and incidence, Notably, the patient’s occupational environment played a crucial role in the diagnosis, as we identified occupational PAP secondary to chronic inhalation of ethylene oxide in a poorly ventilated work setting and inadequate respiratory protection. The patient was administered inhaled filgrastim (1 vial) at four intervals over 30 days, yielding favorable and satisfactory clinical as well as radiological outcomes.
- 25 March 2024
- Published by Wiley in The Prostate
- Vol. 84 (8) , 738-746
CD44 and CD133 protein expression might serve as a prognostic factor for early occurrence castration‐resistant prostate cancer
Background: The occurrence of castration‐resistant prostate cancer (CRPC) varies in patients with advanced prostate cancer (PCa) undergoing androgen deprivation therapy (ADT). The rate of occurrence of CRPC may be related to the presence of prostate cancer stem cells (CSC). Thus, this study aims to evaluate the presence of CSC markers (CD44 and CD133) in histopathology tissue at the time of diagnosis and their correlation with the occurrence of CRPC in patients with advanced PCa within 2 years of ADT.Method: A retrospective case‐control study was conducted to evaluate the incidence of CRPC within 2 years. The inclusion criteria were patients with PCa who had received treatment with ADT and a first‐generation anti‐androgen (AA) for 2 years. We classified patients based on whether they developed CRPC within 2 years (CRPC) of the therapy or did not experience CRPC within 2 years (non‐CRPC) of the therapy. We performed immunohistochemical (IHC) staining for CD44 and CD133 on the prostate biopsy tissue samples.Results: Data were collected from records spanning 2011–2019. We analyzed a total of 65 samples, including 22 patients with CRPC and 43 patients with non‐CRPC who had received treatment with LHRH agonists and AA for up to 2 years. Our findings showed a significant H‐score difference in CD44 protein expression between CRPC prostate adenocarcinoma samples 869 (200–1329) and non‐CRPC 524 (154–1166) (p = 0.033). There was no significant difference in CD133 protein expression between the two groups (p = 0.554). However, there was a significant difference in the nonoccurrence of CRPC between the high expressions of both CD44 and CD133 groups with other expressions of CD44/CD133 groups (25% vs. 75%; p = 0.011; odds ratio = 4.29; 95% confidence interval [1.34, 13.76]).Conclusion: This study found a low expression of at least one CD44/CD133 protein in the patients without early occurrence of CRPC. This result might suggest that CD44/CD133 may function as a potential prognostic marker for PCa, especially in a low expression, to identify patients who have a better prognosis regarding the occurrence of early CRPC.
- 25 March 2024
- Published by Wiley in The Prostate
- Vol. 84 (8) , 738-746
CD44 and CD133 protein expression might serve as a prognostic factor for early occurrence castration‐resistant prostate cancer
Background: The occurrence of castration‐resistant prostate cancer (CRPC) varies in patients with advanced prostate cancer (PCa) undergoing androgen deprivation therapy (ADT). The rate of occurrence of CRPC may be related to the presence of prostate cancer stem cells (CSC). Thus, this study aims to evaluate the presence of CSC markers (CD44 and CD133) in histopathology tissue at the time of diagnosis and their correlation with the occurrence of CRPC in patients with advanced PCa within 2 years of ADT.Method: A retrospective case‐control study was conducted to evaluate the incidence of CRPC within 2 years. The inclusion criteria were patients with PCa who had received treatment with ADT and a first‐generation anti‐androgen (AA) for 2 years. We classified patients based on whether they developed CRPC within 2 years (CRPC) of the therapy or did not experience CRPC within 2 years (non‐CRPC) of the therapy. We performed immunohistochemical (IHC) staining for CD44 and CD133 on the prostate biopsy tissue samples.Results: Data were collected from records spanning 2011–2019. We analyzed a total of 65 samples, including 22 patients with CRPC and 43 patients with non‐CRPC who had received treatment with LHRH agonists and AA for up to 2 years. Our findings showed a significant H‐score difference in CD44 protein expression between CRPC prostate adenocarcinoma samples 869 (200–1329) and non‐CRPC 524 (154–1166) (p = 0.033). There was no significant difference in CD133 protein expression between the two groups (p = 0.554). However, there was a significant difference in the nonoccurrence of CRPC between the high expressions of both CD44 and CD133 groups with other expressions of CD44/CD133 groups (25% vs. 75%; p = 0.011; odds ratio = 4.29; 95% confidence interval [1.34, 13.76]).Conclusion: This study found a low expression of at least one CD44/CD133 protein in the patients without early occurrence of CRPC. This result might suggest that CD44/CD133 may function as a potential prognostic marker for PCa, especially in a low expression, to identify patients who have a better prognosis regarding the occurrence of early CRPC.
- Open Access
- 21 October 2022
- Published by Ikatan Dokter Indonesia in Journal Of The Indonesian Medical Association
- Vol. 72 (4) , 151-156
Keterbatasan Metode Diagnostik Patologi Anatomik dalam bidang Transplantasi Ginjal di Indonesia
Keterbatasan Metode Diagnostik Patologi Anatomik dalam bidang Transplantasi Ginjal di Indonesia
- 21 October 2022
- Published by Ikatan Dokter Indonesia in Journal Of The Indonesian Medical Association
- Vol. 72 (4) , 151-156
Open AccessKeterbatasan Metode Diagnostik Patologi Anatomik dalam bidang Transplantasi Ginjal di Indonesia
Keterbatasan Metode Diagnostik Patologi Anatomik dalam bidang Transplantasi Ginjal di Indonesia
- Open Access
- 4 October 2022
- Published by S. Karger AG in Case Reports in Nephrology and Dialysis
- Vol. 12 (3) , 167-177
Rituximab, Mycophenolic Acid, and Calcineurin Inhibitors Achieve Long-Term Remission in Pediatric Focal Segmental Glomerulosclerosis with Steroid-Resistant and Frequently Relapsing Nephrotic Syndrome: A Report of Two Cases
Studies investigating the effect of rituximab in children with nephrotic syndrome (NS) due to focal segmental glomerulosclerosis (FSGS) have reported conflicting results, with some concluding that patients may require additional immunosuppressive therapy to achieve and/or maintain long-term remission. We report successful treatment of pediatric FSGS with rituximab infusions, followed by maintenance immunosuppression with mycophenolic acid (MPA) and a calcineurin inhibitor (CNI) in 1 patient with refractory steroid-resistant NS (SRNS), and one with frequently relapsing NS (FRNS). Case 1 is a patient with refractory SRNS due to FSGS. MPA and tacrolimus induced complete remission within 6 months following rituximab treatment. Remission was maintained for over 2 years, and the patient’s kidney function and body height also returned to normal ranges within this time. Case 2 is a patient with FRNS due to FSGS, who was treated with rituximab followed by MPA and cyclosporine, which successfully prevented relapses for 18 months, that is, at the end point of the observation. Our case report demonstrates that rituximab and a combination of CNIs and MPA can be effective in achieving complete remission in pediatric refractory SRNS and sustaining remission in pediatric FSGS with FRNS and SRNS for several years. This treatment regimen has the advantage of eliminating the need for long-term high-dose steroid treatments, allowing 1 patient to achieve normal growth and recover from other adverse steroid effects.
- 4 October 2022
- Published by S. Karger AG in Case Reports in Nephrology and Dialysis
- Vol. 12 (3) , 167-177
Open AccessRituximab, Mycophenolic Acid, and Calcineurin Inhibitors Achieve Long-Term Remission in Pediatric Focal Segmental Glomerulosclerosis with Steroid-Resistant and Frequently Relapsing Nephrotic Syndrome: A Report of Two Cases
Studies investigating the effect of rituximab in children with nephrotic syndrome (NS) due to focal segmental glomerulosclerosis (FSGS) have reported conflicting results, with some concluding that patients may require additional immunosuppressive therapy to achieve and/or maintain long-term remission. We report successful treatment of pediatric FSGS with rituximab infusions, followed by maintenance immunosuppression with mycophenolic acid (MPA) and a calcineurin inhibitor (CNI) in 1 patient with refractory steroid-resistant NS (SRNS), and one with frequently relapsing NS (FRNS). Case 1 is a patient with refractory SRNS due to FSGS. MPA and tacrolimus induced complete remission within 6 months following rituximab treatment. Remission was maintained for over 2 years, and the patient’s kidney function and body height also returned to normal ranges within this time. Case 2 is a patient with FRNS due to FSGS, who was treated with rituximab followed by MPA and cyclosporine, which successfully prevented relapses for 18 months, that is, at the end point of the observation. Our case report demonstrates that rituximab and a combination of CNIs and MPA can be effective in achieving complete remission in pediatric refractory SRNS and sustaining remission in pediatric FSGS with FRNS and SRNS for several years. This treatment regimen has the advantage of eliminating the need for long-term high-dose steroid treatments, allowing 1 patient to achieve normal growth and recover from other adverse steroid effects.
- Open Access
- 12 September 2022
- Published by MDPI AG in Applied Sciences
- Vol. 12 (18) , 9141
Ameliorative Effects of Annona muricata Leaf Ethanol Extract on Renal Morphology of Alloxan-Induced Mice
Diabetes mellitus (DM) is a chronic metabolic disorder characterized by hyperglycemia, which affects multiple tissues including kidneys. Soursop leaves (Annona muricata) are known to have antidiabetic potential, but their molecular and cellular effects are poorly characterized. We identified the bioactive compounds in soursop leaf ethanol extract (SLEE). The SLEE substances demonstrated the total alkaloid and total flavonoid contents. Twelve bioactive compounds profiles were identified in SLEE classified as alkaloid, flavonol glycoside, and monoterpenoid lactone derivatives. The SLEE treatments in mice were performed by dividing Swiss Webster mice into five groups, including negative and positive controls and three experimental groups provided with SLEE (doses 150, 300, and 600 mg/kg BW) for 14 days. The mice in the experimental groups were treated with alloxan to induce diabetes. The renal samples were stained for H&E for morphological changes. However, 600 mg/kg of SLEE showed a significant effect (p < 0.05) on the height of the Bowman’s space and prevented the tubularization of the left kidney’s glomerulus (p < 0.05). Altogether, we report no significant difference in the glomerular diameter, the thickness of the proximal convoluted tubules, the height of the Bowman’s space, and the glomerular tubularization after 14 days of treatment with SLEE.
- 12 September 2022
- Published by MDPI AG in Applied Sciences
- Vol. 12 (18) , 9141
Open AccessAmeliorative Effects of Annona muricata Leaf Ethanol Extract on Renal Morphology of Alloxan-Induced Mice
Diabetes mellitus (DM) is a chronic metabolic disorder characterized by hyperglycemia, which affects multiple tissues including kidneys. Soursop leaves (Annona muricata) are known to have antidiabetic potential, but their molecular and cellular effects are poorly characterized. We identified the bioactive compounds in soursop leaf ethanol extract (SLEE). The SLEE substances demonstrated the total alkaloid and total flavonoid contents. Twelve bioactive compounds profiles were identified in SLEE classified as alkaloid, flavonol glycoside, and monoterpenoid lactone derivatives. The SLEE treatments in mice were performed by dividing Swiss Webster mice into five groups, including negative and positive controls and three experimental groups provided with SLEE (doses 150, 300, and 600 mg/kg BW) for 14 days. The mice in the experimental groups were treated with alloxan to induce diabetes. The renal samples were stained for H&E for morphological changes. However, 600 mg/kg of SLEE showed a significant effect (p < 0.05) on the height of the Bowman’s space and prevented the tubularization of the left kidney’s glomerulus (p < 0.05). Altogether, we report no significant difference in the glomerular diameter, the thickness of the proximal convoluted tubules, the height of the Bowman’s space, and the glomerular tubularization after 14 days of treatment with SLEE.
- Open Access
- 11 November 2021
- Published by Elsevier in Urology Case Reports
- Vol. 40, 101944
Retroperitoneoscopic proximal ureter resection and ureteroureterostomy as an alternative management for upper tract urothelial carcinoma: A case report
- 11 November 2021
- Published by Elsevier in Urology Case Reports
- Vol. 40, 101944
Open AccessRetroperitoneoscopic proximal ureter resection and ureteroureterostomy as an alternative management for upper tract urothelial carcinoma: A case report
- Open Access
- 14 October 2021
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 88 (C) , 106493
Adenocarcinoma mucinosum of extrophy bladder
Introduction: Bladder exstrophy is a rare congenital anomaly while, bladder adenocarcinoma mucinous type is a rare type of bladder cancer, with aggressive behavior and inadequate response to radiation and chemotherapy. In extremely rare cases, untreated bladder exstrophy could transform into bladder mucinous adenocarcinoma. Case presentation: We report a case of a 41-year-old male with untreated bladder exstrophy that transformed into mucinous adenocarcinoma. The patient also had epispadias and a right inguinal hernia. Joint procedures were conducted to perform radical cystectomy, total penectomy and W-Pouch continent urostomy, inguinal hernia repair, osteotomy, and keystone and scrotal flap by split-thickness skin graft (STSG) for wound closure. The patient progressed well after surgery, two months after initial procedure, nephrostomies were conducted due to pouches stenosis. Due to the government's limited transportation and lockdown policy, as the Covid-19 pandemic occurred, the patient could not come to the hospital for routine follow-up and died nine-month after surgery. Clinical discussion: Bladder exstrophy is one of the risk factors of bladder cancer. Transformation of bladder exstrophy into mucinous adenocarcinoma is extremely rare, as the case is the first case to be discovered in Indonesia. Surgery, followed with a strict follow-up regime, is mainstay of treatment in this type of malignancy. Conclusion: Adenocarcinoma of mucinous type is a scarce type of bladder exstrophy malignancies. A multidiscipline approach is mandatory in these cases. Strict and regular follow up are suggested for these cases. Highlights:
- 14 October 2021
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 88 (C) , 106493
Open AccessAdenocarcinoma mucinosum of extrophy bladder
Introduction: Bladder exstrophy is a rare congenital anomaly while, bladder adenocarcinoma mucinous type is a rare type of bladder cancer, with aggressive behavior and inadequate response to radiation and chemotherapy. In extremely rare cases, untreated bladder exstrophy could transform into bladder mucinous adenocarcinoma. Case presentation: We report a case of a 41-year-old male with untreated bladder exstrophy that transformed into mucinous adenocarcinoma. The patient also had epispadias and a right inguinal hernia. Joint procedures were conducted to perform radical cystectomy, total penectomy and W-Pouch continent urostomy, inguinal hernia repair, osteotomy, and keystone and scrotal flap by split-thickness skin graft (STSG) for wound closure. The patient progressed well after surgery, two months after initial procedure, nephrostomies were conducted due to pouches stenosis. Due to the government's limited transportation and lockdown policy, as the Covid-19 pandemic occurred, the patient could not come to the hospital for routine follow-up and died nine-month after surgery. Clinical discussion: Bladder exstrophy is one of the risk factors of bladder cancer. Transformation of bladder exstrophy into mucinous adenocarcinoma is extremely rare, as the case is the first case to be discovered in Indonesia. Surgery, followed with a strict follow-up regime, is mainstay of treatment in this type of malignancy. Conclusion: Adenocarcinoma of mucinous type is a scarce type of bladder exstrophy malignancies. A multidiscipline approach is mandatory in these cases. Strict and regular follow up are suggested for these cases. Highlights:
- Open Access
- 1 July 2021
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 84, 106083
Cystoscopy-assisted laparoscopic partial cystectomy for muscle-invasive bladder cancer: Initial experience in Cipto Mangunkusumo Hospital, Jakarta
We report the experience with patients of urachal adenocarcinoma of the bladder, a rare malignancy in the urinary bladder, treated with laparoscopic partial cystectomy. Solitary transitional cell carcinoma (TCC) of the dome/anterior wall of the bladder in some cases. As compared to radical surgery, partial cystectomy has a lower morbidity rate and similar oncological outcomes. We present our experience with laparoscopic partial cystectomy (LPC) in patients with urachal adenocarcinoma. Until being admitted to the hospital, a 60-year-old woman had been suffering from painless, sporadic gross hematuria for the previous year. Her physical examination was undistinguished. Computed tomography revealed an enhancing firmly bordered mass on the anterior-superior aspect of the bladder wall. The patient then underwent cystoscopy and laparoscopic partial cystectomy simultaneously. Based on our first experience in LPC, we suggest that cystoscopy assisted LPC is a reasonable and safe procedure with fewer complications and does not extend the operating time. The procedure's effectiveness hinges on the patient's selection. However, many cases needed to emphasize the effectiveness and safety of LPC.
- 1 July 2021
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 84, 106083
Open AccessCystoscopy-assisted laparoscopic partial cystectomy for muscle-invasive bladder cancer: Initial experience in Cipto Mangunkusumo Hospital, Jakarta
We report the experience with patients of urachal adenocarcinoma of the bladder, a rare malignancy in the urinary bladder, treated with laparoscopic partial cystectomy. Solitary transitional cell carcinoma (TCC) of the dome/anterior wall of the bladder in some cases. As compared to radical surgery, partial cystectomy has a lower morbidity rate and similar oncological outcomes. We present our experience with laparoscopic partial cystectomy (LPC) in patients with urachal adenocarcinoma. Until being admitted to the hospital, a 60-year-old woman had been suffering from painless, sporadic gross hematuria for the previous year. Her physical examination was undistinguished. Computed tomography revealed an enhancing firmly bordered mass on the anterior-superior aspect of the bladder wall. The patient then underwent cystoscopy and laparoscopic partial cystectomy simultaneously. Based on our first experience in LPC, we suggest that cystoscopy assisted LPC is a reasonable and safe procedure with fewer complications and does not extend the operating time. The procedure's effectiveness hinges on the patient's selection. However, many cases needed to emphasize the effectiveness and safety of LPC.